期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

索利那新对前列腺增生症患者TURP术后膀胱痉挛的防治作用观察 被引量：11

下载PDF
导出
摘要 目的探讨琥珀酸索利那新防治良性前列腺增生症经尿道前列腺电切术(TURP)术后膀胱痉挛的临床效果。方法将68例前列腺增生症行TURP术的患者随机分为两组。观察组(34例)于术后当日起口服索利那新5 mg,1次/d。对照组(34例)术后出现膀胱痉挛疼痛剧烈时肌肉注射哌替啶50 mg,比较两组术后72 h内膀胱痉挛发生率、每例出现的次数及持续时间,拔尿管时间及不良反应发生率。结果术后72 h内观察组现膀胱痉挛发生率及出现次数、持续时间均少于对照组,拔尿管时间短于对照组;药物相关性不良反应发生率低于对照组,P均<0.05。结论索利那新对预防和缓解TURP术后膀胱痉挛效果显著;且不良反应发生率低。
作者 王小磊 李黎明
机构地区 天津医科大学总医院 海洋石油总医院
出处 《山东医药》 CAS 2013年第42期65-66,共2页 Shandong Medical Journal
关键词 经尿道前列腺电切术 膀胱痉挛 索利那新
分类号 R697 [医药卫生—泌尿科学]
  • 相关文献

参考文献11

  • 1de Nunzio C, Franco G, Rocchegiani A, et al. The evolution of de- trusor overactivity ter watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction [ J]. J Urol, 2003,169 (2) :535-539.
  • 2赵利涛,郭茂源,邱浩,唐司亚,孙忠杰,王元元,刘志宇.琥珀酸索利那新治疗TUR-P术后膀胱痉挛20例疗效观察[J].大连医科大学学报,2011,33(1):61-63. 被引量：18
  • 3Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin With or Without toherodine in men With symptomatic bladder outlet obstruction and an overactive bladder[J] . BJU Int, 2004,94(6) :817-820.
  • 4郭煜.膀胱痉挛的处理对策与进展[J].现代临床医学,2006,32(5):384-386. 被引量：14
  • 5Osamu Y, Osamu N, Masayuki T. et al. Clinical guidelines for overactive bladder [ J ]. J Urol, 2009,16 ( 2 ) : 126-142.
  • 6Malhotra B, Gandehnan K, Sachse R, et al. The design and de- velopment of fesoterodinc as a prodrug of 5-hydroxymethyl tolterod- ine (5-HMT), the active metabolite of tolterodine [ J ]. Cuir Med Chem, 2009,16 ( 33 ) :4481-4489.
  • 7Yterschom S, Stothers L,Carlson K, el al. Tolerability of 5rag Solifena- cin once daily versus 5rag oxybutynin immediate release 3 times daily : Results of the vector trial[J]. J Urol, 2010,183(5) :1892-1898.
  • 8伊庆同,龚旻,胡巍,田斌强,祝凤明,王天如,顾建军,陈楚红,郭建华,王华,陈长青.索利那新治疗经尿道前列腺电切术后膀胱过度活动症的疗效分析[J].中华泌尿外科杂志,2011,32(6):415-418. 被引量：17
  • 9吴士良,肖云翔,段继宏,丁强,孙颖浩,黄翼然,宋波,蔡松良,那彦群.索利那新治疗尿急及急迫性尿失禁的有效性和安全性分析[J].中华泌尿外科杂志,2009,30(9):630-634. 被引量：71
  • 10Yoshihiko I, Akira Y. Comparison of muscarinic receptor selectivi- ty of so|ifenaein and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice[J]. Eur J Phanacol, 2009,615 ( 1-3 ) :201-206.

二级参考文献56

  • 1刘婷,曹志成.三七冲洗液浓度对前列腺术后膀胱痉挛的影响——附护理体会[J].辽宁中医杂志,2005,32(4):365-366. 被引量：3
  • 2王越,周鹏.吲哚美辛栓在前列腺增生症术后的临床应用及疗效观察[J].社区医学杂志,2005,3(11):79-79. 被引量：10
  • 3Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function, report from the standardisaton subcommittee of the International Continence Society. Neurourol Urodyn, 2002, 21: 167-178.
  • 4Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep, 2002, 3:434- 438.
  • 5Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int, 2006, 97: 96-100.
  • 6Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100: 987-1006.
  • 7Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol, 2002, 366: 97-103.
  • 8Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmaeol, 2004, 492:243- 250.
  • 9Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci, 2004, 74: 843-853.
  • 10Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol, 2004, 44:1023- 1033.

共引文献115

同被引文献98

  • 1宋伟,赵勇,王慕文,李连军,曲华伟,崔子连.琥珀酸索利那新治疗膀胱肿瘤选择性光汽化术后膀胱痉挛的疗效观察[J].泌尿外科杂志（电子版）,2013,5(4):19-21. 被引量：3
  • 2夏小萍,徐福涛,马正良,吴浩,朱魏,夏毅平.丁丙诺啡与布比卡因联合用于前列腺增生术后硬膜外镇痛的临床观察[J].江苏医药,2006,32(1):27-29. 被引量：4
  • 3孙世林.葱苓膏穴位贴敷结合针刺治疗脑卒中后尿潴留的临床观察[D].黑龙江中医药大学,2012.
  • 4王成,赵定平.前列腺摘除术后膀胱痉挛防治方法的探讨[J].江苏医药,2000,26(7):569-570.
  • 5Tehranchi A,Rezaei Y,Shojaee R.Tolterodine to relieve urinary symptoms following transurethral resection of the prostate:a double-blind placebo-controlled randomized clinical trial[J].Korean J Urol,2014,55(4):260-264.
  • 6Kara C,Resorlu B,Cicekbilek I,et al.Analgesic efficacy and safety of nonsteroidal anti-inflammatory drugs after transurethral resection of prostate[J].Int Braz J Urol,2010,36(1):49-54.
  • 7Mazaris EM,Varkarakis I,Chrisofos M,et al.Use of nonsteroidal anti-inflammatory drugs after radical retropubic prostatectomy:aprospective,randomized trial[J].Urology,2008,72(6):1293-1297.
  • 8Dhingra N,Bhagwat D. Benign prostatic hyperplasia : An overview of existing treatment [J ]. Indian Journal of Pharmacology ,2011,43 (01):6-12.
  • 9Zhao YR,Liu WZ,Guralnick M, et al. Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction [ J ]. Int J Urol,2014,21(10) : 1035 -1040.
  • 10Doroshyenko 0,Fuhr U. Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin[ J]. Clin Pharmacokinet,2009 ,48 (5): 281 -302.

引证文献11

二级引证文献74

山东医药
2013年 第42期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部